Prelude Therapeutics INC (PRLD) SEC Filings — 2025

Filings

• Prelude Narrows Losses, Boosts Revenue Amid Strategic R&D Shift — 10-Q · Nov 12, 2025
• Prelude Therapeutics INC 8-K Filing — 8-K · Nov 4, 2025
• Prelude Therapeutics Announces CMO Departure, Appoints Interim — 8-K · Oct 17, 2025
• Prelude Therapeutics Files 8-K — 8-K · Sep 19, 2025
• Prelude Therapeutics' Cash Dwindles Amidst Mounting Losses — 10-Q · Aug 14, 2025
• Prelude Therapeutics Appoints New Director — 8-K · Jun 13, 2025
• Prelude Therapeutics Files Q1 2025 10-Q — 10-Q · May 6, 2025
• Prelude Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 29, 2025
• Prelude Therapeutics Files 8-K Report — 8-K · Apr 25, 2025
• Prelude Therapeutics Faces Nasdaq Delisting Notice — 8-K · Mar 28, 2025
• Prelude Therapeutics Files 2024 Annual Report — 10-K · Mar 10, 2025
• Prelude Therapeutics Files 8-K: Officer/Director Changes & Financials — 8-K · Feb 5, 2025